Careers  |  Sign In  |  Register

New First-Trimester Down Syndrome Test Could Be Less Invasive

A new study in Ultrasound in Obstetrics & Gynecology explores the feasibility of using maternal blood cell-free (cf) DNA testing to screen for Down Syndrome and other trisomies at 10 weeks’ gestation. Researchers found that by only taking a simple blood sample, they could successfully test for trisomies 21, 18 and 13 in 95% of cases after only 10 weeks. The study concluded that “routine screening for trisomies by cfDNA testing at 10 weeks is feasible, allowing diagnosis of aneuploidies and the option of pregnancy termination within the first trimester.”

Read the study in Ultrasound in Obstetrics & Gynecology.